Company Profile
Apellis Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- APLS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
41.03 USD (-0.07%)
Close
Last updated: May 13, 2026
5.25B USD
Market cap
Why the stock is moving
Current closing-price context is not available for APLS.
Company overview
Complement C3 Biology
Apellis Pharmaceuticals develops medicines that inhibit complement protein C3, a central control point in the complement cascade. Its portfolio applies the same core biology to retinal, hematologic and renal diseases.
SYFOVRE
SYFOVRE is an intravitreal pegcetacoplan therapy and the first approved treatment for geographic atrophy secondary to age-related macular degeneration. Apellis retains worldwide ophthalmology rights and is developing a prefilled-syringe presentation.
EMPAVELI
EMPAVELI, or systemic pegcetacoplan, is approved in the United States for paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. Sobi commercializes systemic pegcetacoplan outside the United States.
Rare-Kidney Expansion
Pivotal studies are evaluating EMPAVELI in focal segmental glomerulosclerosis and delayed graft function. These programs extend systemic C3 inhibition into additional kidney diseases with substantial complement involvement.
Next-Generation Pipeline
APL-3007 is being combined with SYFOVRE in Phase 2 to achieve broader complement blockade in the retina and choroid. APL-90992 is a preclinical base-editing program intended to create a one-time treatment targeting the neonatal Fc receptor.
Future catalysts
Regulatory submission for the SYFOVRE prefilled syringe planned in the first half of 2026.
IND submission for APL-90992 planned in the second half of 2026.
Topline Phase 2 data for SYFOVRE plus APL-3007 expected in 2027.
Recent news
- 01
- 02
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
Source: Apellis Pharmaceuticals
- 03
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Source: Apellis Pharmaceuticals
- 04
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
Source: Apellis Pharmaceuticals
- 05
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
Source: Apellis Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Apellis Pharmaceuticals (APLS)?
Apellis Pharmaceuticals (APLS) most recently closed at 41.03 USD, a -0.07% move versus the previous session.
What is the market cap of Apellis Pharmaceuticals (APLS)?
Apellis Pharmaceuticals currently has a market capitalization of 5.25B USD on BioPharmSignal.
What does Apellis Pharmaceuticals do?
Complement C3 Biology Apellis Pharmaceuticals develops medicines that inhibit complement protein C3, a central control point in the complement cascade. Its portfolio applies the same core biology to retinal, hematologic and renal diseases. SYFOVRE SYFOVRE is an intravitreal pegcetacoplan therapy and the first approved treatment for geographic atrophy...
On which exchange is APLS stock listed?
Apellis Pharmaceuticals (APLS) is associated with NASDAQ, United States, Biopharma.
What is APL-3007?
Topline Phase 2 data for SYFOVRE plus APL-3007 expected in 2027.
Which conditions is Apellis Pharmaceuticals targeting with APL-3007?
Apellis Pharmaceuticals is associated with ophthalmology based on its company overview and current catalyst commentary.
How does Apellis Pharmaceuticals describe recent progress with APL-3007?
Topline Phase 2 data for SYFOVRE plus APL-3007 expected in 2027.
What is APL-90992?
APL-90992 is a preclinical base-editing program intended to create a one-time treatment targeting the neonatal Fc receptor.